External reports (aggregated public sources), Value Investors Club

Value Investors Club

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>ESPR pharmaceutical company has two commercialized drugs and could potentially double in value with a $300 million milestone payout</li><li>Ongoing litigation with DSE due to failure to meet payment obligations under a milestone agreement</li><li>ESPR entitled to a Regulatory Milestone Payment pending regulatory approval for a licensed product in DSE territory, making it a strong investment opportunity with potential for high returns</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

ESPR pharmaceutical company has two commercialized drugs and could potentially double in value with a $300 million milestone payoutOngoing litigation with DSE due to failure to meet payment obligations under a milestone agreementESPR entitled to a Regulatory Milestone Payment pending regulatory approval for a licensed product in DSE territory, making it a strong investment opportunity with potential for high returnsThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Esperion Therapeutics Inc (ESPR) - Friday, Dec 22, 2023